Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma Journal Article

Authors: Iwamoto, F. M.; Schwartz, J.; Pandit-Taskar, N.; Peak, S.; Divgi, C. R.; Zelenetz, A. D.; Humm, J.; Abrey, L. E.
Article Title: Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma
Abstract: BACKGROUND. Therapeutic options for refractory or recurrent primary central nervous system lymphoma (PCNSL) are limited. The blood-brain barrier makes many agents used in systemic lymphomas ineffective in CNS lymphomas. The objective of this study was to determine whether intravenous radioimmunotherapy using anti-CD20 antibody can be delivered to PCNSL. METHODS. This was a single-institution prospective study. Indium-111 ibritumomab tiuxetan was used for imaging and dosimetry. Yttrium-90 ibritumomab tiuxetan at doses of 0.3 to 0.4 mCi/kg were subsequently given for the treatment of recurrent or refractory PCNSL. 111In data were used to estimate radiation doses to lesions delivered by 90Y ibritumomab tiuxetan therapy. RESULTS. Six patients (4 men, 2 women) with a median age of 60 years and median Karnofsky performance status of 70 received both indium-111 and yttrium-90 ibritumomab tiuxetan. The median absorbed dose delivered to the CNS lymphoma was 701 cGy compared with 70 cGy to normal brain. The median progression-free and overall survival times were 6.8 weeks and 14.3 weeks, respectively. CONCLUSIONS. The results from this study suggest that it may be feasible to deliver radiolabeled monoclonal anti-CD20 antibodies as a component of therapy for PCNSL. © 2007 American Cancer Society.
Keywords: adult; cancer survival; clinical article; controlled study; treatment response; aged; disease-free survival; middle aged; survival rate; disease course; cisplatin; drug efficacy; drug safety; unspecified side effect; cancer radiotherapy; disease free survival; radiation dose; primary central nervous system lymphoma; cytarabine; ibritumomab tiuxetan; methotrexate; rituximab; temozolomide; drug megadose; neuroimaging; nuclear magnetic resonance imaging; outcome assessment; follow up; tumor volume; etoposide; radiotherapy dosage; recurrence; combination chemotherapy; central nervous system neoplasms; b lymphocyte; monoclonal antibodies; indium radioisotopes; isotope labeling; dosimetry; blood brain barrier; blood-brain barrier; methylprednisolone; radioimmunotherapy; indium 111; yttrium radioisotopes; hematologic disease; non-hodgkin lymphoma; radiation dosimetry; yttrium 90; myelodysplasia; cd20 antibody
Journal Title: Cancer
Volume: 110
Issue: 11
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2007-12-01
Start Page: 2528
End Page: 2534
Language: English
DOI: 10.1002/cncr.23077
PUBMED: 17932895
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 17" - "Export Date: 17 November 2011" - "CODEN: CANCA" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Scott Jason Peak
    4 Peak
  2. Chaitanya Divgi
    163 Divgi
  3. Fabio M Iwamoto
    36 Iwamoto
  4. Andrew D Zelenetz
    647 Zelenetz
  5. Lauren E Abrey
    276 Abrey
  6. John Laurence Humm
    381 Humm